Alpha-GPC (L-Alpha-Glycerylphosphorylcholine)

Alpha-GPC (L-alpha-glycerylphosphorylcholine, or choline alphoscerate) is a choline-rich compound that crosses the blood-brain barrier and raises brain levels of acetylcholine, the neurotransmitter central to memory and attention. On that mechanism it has been built into a popular nootropic and pre-workout ingredient, promoted for studying, focus and the 'mind-muscle connection,' and in several countries it is even a prescription treatment for cognitive decline. ORIA nonetheless places it at caution — one notch below okay — and the reasoning is a deliberate risk-benefit weighing rather than any single scary fact. On the benefit side, the evidence is underwhelming for the healthy people who mostly buy it: the better-quality data sit in Alzheimer's and clinical populations, while studies in healthy adults are small, few and inconsistent, with most failing to demonstrate a clear cognitive gain. On the risk side sits an unusually large signal. A population study using South Korea's national health database followed more than 12 million adults aged 50 and over and found that alpha-GPC users had a dose-responsive increase in 10-year stroke risk — roughly 46% higher overall — even after adjusting for traditional cardiovascular risk factors. There is a coherent mechanism: choline can be converted by gut microbes into trimethylamine-N-oxide (TMAO), a metabolite linked to atherosclerosis. Honesty requires noting the limits: this is an observational association, not proof of cause, the study comes from a single country's records, and a subsequent cohort in people with mild cognitive impairment found no significant stroke difference after careful matching — so the question is genuinely unsettled. But ORIA's job is to weigh facts the way a careful physician would, and when a supplement's benefit for a healthy person is weak and the unresolved downside is stroke, 'proceed with caution' is the honest call, not 'this is fine.' Anyone older or carrying cardiovascular or cerebrovascular risk should specifically discuss alpha-GPC with their doctor before taking it. [This is a judgment call: a reasonable clinician could instead grade it okay with a prominent stroke flag; the grade is override-able.] Verdict: a heavily-marketed focus aid whose modest, shaky upside does not clearly outweigh a serious safety question — caution.